Abstract
Against the backdrop of the ever-changing Staphylococcal resistance pattern, clindamycin remains a viable therapeutic alternative Variation of Clindamycin drug resistance patterns with geographic area make inducible clindamycin resistance testing imperative for all staphylococcal isolates to avoid therapeutic failure. This was a prospective study conducted over a period of 1.5 years from January 2021 until June 2022. Prevalence of different MLSB Phenotypes of Staphylococcus aureus isolates was determined by standard disc diffusion method as per CLSI guidelines. Pyogenic samples received in the Microbiology lab that yielded Staphylococcus aureus were further tested for the presence of clindamycin resistance by disc diffusion method. Out of 6586 total pyogenic and respiratory specimens received in the lab, Staphylococcus aureus was yielded in 752 samples. On further testing for the MLSB phenotypes, 16.3% isolates were found to be iMLSB, 19.28% were cMLSB, 43.1% were of MSB type. ICR screening will reduce the unessential subjection of the patient to the antibiotic, and would prevent unnecessary adverse effects in the patients.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
